STAA Share Price Performance
US$0
-28.08 (-100.00%)
Price US$0
Fair ValueUS$29.67
Share Pricen/a
STAAR Surgical Company Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
STAA Community Narratives
AN
Fair Value
·Fair Value US$29.67 23.6% undervalued intrinsic discount
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$20 13.3% overvalued intrinsic discount
Geopolitical Tensions And Regulatory Pressures Will Depress Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$39.24 42.2% undervalued intrinsic discount
Growing Myopia And Aging Population Will Expand Vision Correction Opportunities
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
STAAR Surgical
13.3% overvalued intrinsic discount
Geopolitical Tensions And Regulatory Pressures Will Depress Margins
View narrativeAN
Updated 29 Jul
STAAR Surgical
42.2% undervalued intrinsic discount
Growing Myopia And Aging Population Will Expand Vision Correction Opportunities
View narrativeAN
Updated 16 Jun
STAAR Surgical
23.6% undervalued intrinsic discount
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
View narrativeAN
Updated 2 Jun
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
STAA: Sector Procedure Risks And China Uncertainty Will Limit Future Upside
Fair Value: US$20 13.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
STAA: China Rebound After Q1 Inflection Will Drive Future Re Rating
Fair Value: US$39.24 42.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
STAA: China Recovery And Profitability Improvements Will Temper Prior Bearish Reassessment
Fair Value: US$29.67 23.6% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
STAAR Surgical Company Key Details
About STAA
- Founded
- 1982
- Employees
- 921
- CEO
- WebsiteView website
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
